Bank of America’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.41M | Buy |
676,795
+225,637
| +50% | +$3.03M | ﹤0.01% | 3093 |
|
|
2025
Q4 | $5.68M | Sell |
451,158
-211,737
| -32% | -$2.42M | ﹤0.01% | 3285 |
|
|
2025
Q3 | $6.64M | Buy |
662,895
+118,003
| +22% | +$1.06M | ﹤0.01% | 3733 |
|
|
2025
Q2 | $4.41M | Buy |
544,892
+7,540
| +1% | +$56.8K | ﹤0.01% | 4030 |
|
|
2025
Q1 | $4.5M | Sell |
537,352
-19,529
| -4% | -$163K | ﹤0.01% | 3918 |
|
|
2024
Q4 | $4.41M | Buy |
556,881
+382,222
| +219% | +$3.21M | ﹤0.01% | 3712 |
|
|
2024
Q3 | $1.45M | Sell |
174,659
-361,403
| -67% | -$2.83M | ﹤0.01% | 4798 |
|
|
2024
Q2 | $3.4M | Buy |
536,062
+314,727
| +142% | +$2M | ﹤0.01% | 3979 |
|
|
2024
Q1 | $1.34M | Buy |
221,335
+39,308
| +22% | +$222K | ﹤0.01% | 4736 |
|
|
2023
Q4 | $1.1M | Sell |
182,027
-76,583
| -30% | -$341K | ﹤0.01% | 4901 |
|
|
2023
Q3 | $1.09M | Buy |
258,610
+148,589
| +135% | +$554K | ﹤0.01% | 4763 |
|
|
2023
Q2 | $341K | Sell |
110,021
-15,966
| -13% | -$34K | ﹤0.01% | 5506 |
|
|
2023
Q1 | $175K | Sell |
125,987
-817,599
| -87% | -$1.63M | ﹤0.01% | 5993 |
|
|
2022
Q4 | $1.88M | Buy |
943,586
+873,690
| +1,250% | +$1.96M | ﹤0.01% | 4311 |
|
|
2022
Q3 | $141K | Sell |
69,896
-83
| -0.1% | -$233 | ﹤0.01% | 6170 |
|
|
2022
Q2 | $222K | Buy |
69,979
+36,796
| +111% | +$133K | ﹤0.01% | 6012 |
|
|
2022
Q1 | $138K | Sell |
33,183
-29,779
| -47% | -$132K | ﹤0.01% | 6686 |
|
|
2021
Q4 | $302K | Buy |
62,962
+22,134
| +54% | +$110K | ﹤0.01% | 6238 |
|
|
2021
Q3 | $217K | Buy |
40,828
+4,635
| +13% | +$23.3K | ﹤0.01% | 6248 |
|
|
2021
Q2 | $185K | Sell |
36,193
-43,292
| -54% | -$246K | ﹤0.01% | 6145 |
|
|
2021
Q1 | $535K | Buy |
79,485
+44,531
| +127% | +$247K | ﹤0.01% | 5302 |
|
|
2020
Q4 | $160K | Sell |
34,954
-160,902
| -82% | -$713K | ﹤0.01% | 5729 |
|
|
2020
Q3 | $759K | Sell |
195,856
-214,383
| -52% | -$917K | ﹤0.01% | 4411 |
|
|
2020
Q2 | $1.95M | Sell |
410,239
-90,047
| -18% | -$371K | ﹤0.01% | 3651 |
|
|
2020
Q1 | $1.74M | Sell |
500,286
-221,434
| -31% | -$938K | ﹤0.01% | 3587 |
|
|
2019
Q4 | $3.48M | Buy |
721,720
+485,692
| +206% | +$1.69M | ﹤0.01% | 3565 |
|
|
2019
Q3 | $685K | Sell |
236,028
-256,792
| -52% | -$896K | ﹤0.01% | 4842 |
|
|
2019
Q2 | $3.53M | Buy |
492,820
+13,763
| +3% | +$141K | ﹤0.01% | 3553 |
|
|
2019
Q1 | $6.79M | Buy |
479,057
+174,733
| +57% | +$2.31M | ﹤0.01% | 2854 |
|
|
2018
Q4 | $4.12M | Buy |
304,324
+33,136
| +12% | +$597K | ﹤0.01% | 3198 |
|
|
2018
Q3 | $6.02M | Buy |
271,188
+48,854
| +22% | +$1.03M | ﹤0.01% | 3012 |
|
|
2018
Q2 | $3.65M | Buy |
+222,334
| New | +$3.9M | ﹤0.01% | 3448 |
|
Other funds holding AMRX
TGA
VPM
RCMNY
VCM
Bank of America's AMRX Position: Q1 2026 in Review
Bank of America increased its Amneal Pharmaceuticals (AMRX) stake by 50% in Q1 2026, buying an estimated $3.03M and bringing the position to 676,795 shares worth $8.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3093.
Bank of America first reported a position in AMRX in Q2 2018 and has held it in 32 quarters since. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.
- Bank of America held 676,795 shares of Amneal Pharmaceuticals worth $8.41M as of Q1 2026.
- Bank of America bought 225,637 Amneal Pharmaceuticals shares in Q1 2026, an estimated $3.03M.
- Amneal Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3093 holding.
- Bank of America first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
- 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.